A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

Authors

• B H O'Neil
• A J Scott
• W W Ma
• S J Cohen
• L Leichman
• D L Aisner
• A R Menter
• M A Tejani
• J K Cho
• J Granfortuna
• L Coveler
• O O Olowokure
• J C Baranda
• M Cusnir
• P Phillip
• J Boles
• R Nazemzadeh
• M Rarick
• D J Cohen
• J Radford
• L Fehrenbacher
• R Bajaj
• V Bathini
• P Fanta
• J Berlin
• A J McRee
• R Maguire
• F Wilhelm
• M Maniar
• A Jimeno
• C L Gomes
• W A Messersmith

Publication/Presentation Date

12-1-2015

Volume

26

Issue

12

First Page

2505

Last Page

2505

ISSN

1569-8041

Published In/Presented At

O'Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Leichman, L., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J., Coveler, L., Olowokure, O. O., Baranda, J. C., Cusnir, M., Phillip, P., Boles, J., Nazemzadeh, R., Rarick, M., Cohen, D. J., Radford, J., … Messersmith, W. A. (2015). A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer. Annals of oncology : official journal of the European Society for Medical Oncology, 26(12), 2505. https://doi.org/10.1093/annonc/mdv477

Disciplines

Medicine and Health Sciences

PubMedID

26489442

Department(s)

Hematology-Medical Oncology Division

Document Type

Article